Medtronic gets FDA approval for Brainsense device

In Parkinson’s fight, Medtronic’s first-in-the-world adaptive therapy feature wins FDA approval
After decades of development and trials, Medtronic has secured U.S. Food and Drug Administration approval for adaptive technology personalizing treatment of Parkinson’s symptoms using advanced stimulation deep in the brain.
Medtronic gets FDA approval for Brainsense device in Parkinson's patients
Medtronic said Monday the U.S. Food and Drug Administration has approved an adaptive brain-stimulation device as a treatment for people with Parkinson's disease, a major milestone for the technology.
US FDA approves Medtronic's medical device for Parkinson's disease
The U.S. Food and Drug Administration has approved Medtronic's deep brain stimulation system for use in patients with Parkinson's disease, the medical device maker said on Monday.
FDA approves Medtronic’s brain stimulation system for Parkinson’s
The FDA’s authorisation of Medtronic’s BrainSense follows the system’s receipt of a CE mark in Europe last month.
U.S. Deep Brain Stimulation In Parkinson's Disease Market Research 2025-2030 with Competitive Analysis of ABBOTT, Medtronic, and Boston Scientific
The "U.S. Deep Brain Stimulation In Parkinson's Disease Market Size, Share & Trends Analysis Report By Product (Single-channel, Dual-channel), Competitive Analysis, And Segment Forecasts, 2025 - 2030" report has been added to ResearchAndMarkets.
Medtronic wins first FDA nod for adaptive DBS for Parkinson’s
(NYSE: MDT) announced today that the FDA approved its BrainSense adaptive deep brain stimulation (aDBS) platform.
FDA Approves Medtronic’s BrainSense Adaptive Deep Brain Stimulation for Parkinson Disease
The BrainSense adaptive deep brain stimulation system personalizes therapy by dynamically adjusting stimulation based on real-time brain activity to improve Parkinson disease symptom control without manual adjustments.
Medtronic's deep brain stimulation system for Parkinson's disease wins FDA nod
Medtronic (NYSE:MDT) has won FDA approval for a deep brain stimulation system for Parkinson’s disease. The approval is for BrainSense Adaptive deep brain stimulation (DBS)and BrainSense Electrode Identifier.
Medtronic explores options to optimize manufacturing operations amid Trump's tariff threats
Medical device maker Medtronic is looking at options to modify its global manufacturing footprint as part of efforts to ...
We are party agnostic: Medtronic CTO, on weathering geo-political storms
Medtronic's agnostic approach to global challenges, including tariffs and AI, ensures success and innovation in healthcare ...
Why Medtronic Stock Is Sinking Today
Shares of Medtronic ( MDT -6.63%) were sinking 7.3% as of 11:21 a.m. ET on Tuesday. The decline came after the medical device ...
Medtronic Stock Slumps as Sales Miss Estimates
The revenue miss came as sales at Medtronic's Medical Surgical division declined 1.9% to $2.07 billion. The company pointed ...
Parkinson’s Patients Have a New Way to Manage Their Symptoms
T here is still no cure for Parkinson’s disease, but the U.S. Food and Drug Administration (FDA) approved a new deep brain ...
Is Medtronic Stock a Buy?
Medtronic's stock is probably not a jaw-dropping bargain at these prices, but it's an excellent business at a reasonable value. It's safe to call Medtronic a solid buy, especially if you're a ...
devdiscourse3h
Healthcare Dynamics: Challenges and Innovations Amid Global Shifts
A series of important developments in the healthcare sector includes Medtronic adapting to tariff threats, Hims & Hers facing ...
Medtronic expects pressure in surgical unit for fourth quarter, shares fall
Medtronic on Tuesday missed Wall Street estimates for third-quarter revenue due to lower purchases of its surgical devices by ...